Different options for closing wounds, initiating hemostasis and other related applications are emerging in markets outside the well-developed medical markets in Europe, Japan and the U.S.
Below is an example of a novel hemostatic agent, Ankaferd Bloodstopper, a plant-based agent that has been developed by the Istanbul, Turkey, company, Ankaferd Health Products Ltd.
Currently only registered for sale in Turkey and Bosnia/Herzegovina, since the product has not received CE Mark, the question remains whether the product will make it in Western Europe or the U.S., not least of which due to its interesting origin and the fact that its mechanism of action has not yet been elucidated. From "Today’s Zaman" (25 January 2009):
The inventor of this miraculous product, Hüseyin Cahit FÄ±rat, is, interestingly enough, not a medical doctor. He studied economics and was involved in business and journalism but has been engaged in the healing effects of herbs and worked on the formula of ABS for 30 years. Speaking to Sunday’s Zaman in an interview, FÄ±rat said ABS comprises a standardized mixture of galangal, nettles, grape leaves, licorice and thyme, which are mixed together under laboratory conditions. "Although ABS has been confirmed again and again to stop bleeding, the basic mechanism of action for the hemostatic effects of ABS still cannot be explained," he says.
It is worth noting that, for an analogous product, fibrin sealants, the initial market success was not in Europe or the U.S., but Japan, due in part to the social stigma in Japan associated with bleeding and, on the other side, to concerns in the U.S. (not so much for Europe) regarding potential blood-borne viral transmission associated with fibrin sealants.
MedMarket Diligence has published a report on surgical sealants, glues, hemostasis, anti-adhesion and other products. See Report #S175.